Persistent Systems Leads as Top Indian IT and Pharma Firms Draw Up to 80 Percent Revenue from the US

India's corporate heavyweights in the technology and healthcare domains continue to exhibit substantial financial reliance on the United States, with several marquee firms generating between 28% and 80% of their total revenues across the Atlantic. According to market data tracking geographical revenue breakdowns, mid-tier and tier-one IT services providers along with generic drugmakers dominate the list of Indian enterprises most exposed to the US economy.

Pune-based Persistent Systems takes the top spot, earning an overwhelming 80% of its revenue from the US market. It is closely followed by LTIMindtree, which attributes 75% of its turnover to American enterprise clients.

Tech Sector Dominance Across North America

The data underscores that Indian software exporters continue to find their primary growth engine in North America, where enterprise demand for digital transformation, cloud migration, and artificial intelligence remains concentrated. Among tier-one tech majors:

• HCL Technologies secures the third rank with 63% of its revenue flowing from the US.
• Wipro follows closely with approximately 60% of top-line earnings derived stateside.
• Infosys, India’s second-largest software exporter, draws 56% of its business from US-based clients.
• Tata Consultancy Services (TCS) and Tech Mahindra each generate half (50%) of their total revenues from the American market.

While this extensive reach demonstrates the global competitiveness and mission-critical nature of Indian IT services, it also ties Indian index performance closely to US enterprise tech spending, interest rate trajectories set by the Federal Reserve, and work visa policies.

Indian Pharma’s Generic Footprint

Beyond technology, India's pharmaceutical exporters form the second key cohort driving substantial revenues from North America. Supplying a major share of affordable generic drugs and active pharmaceutical ingredients consumed in the US healthcare system, domestic pharma leaders report significant exposure:

• Lupin garners 42% of its revenue from the US market.
• Aurobindo Pharma attributes 41% of its total receipts to American sales.
• Sun Pharmaceutical Industries, the country’s largest drugmaker by market value, generates 28% of its top line from the US.

What This Means for Domestic Investors

For investors on Dalal Street tracking the Nifty 50, Nifty IT, and Nifty Pharma indices, this revenue distribution highlights both a growth corridor and a systemic vulnerability.

A stronger US dollar traditionally aids rupee-denominated realization and operating margins for these firms. However, geopolitical shifts, cross-border tariff debates, US FDA regulatory scrutiny, and corporate budget cutbacks in North America can swiftly impact forward earnings. As Indian corporations deepen bilateral commercial partnerships, portfolio managers will keep a close eye on American corporate earnings and legislative developments to assess risks for export-heavy domestic equities.

Tags: Persistent Systems LTIMindtree Infosys Tata Consultancy Services Sun Pharma Nifty IT